asthma

Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention in children with acute severe asthma — a...

Amgen Inc (NASDAQ: AMGN) shared results from a pooled post-hoc analysis of the NAVIGATOR Phase 3 and PATHWAY Phase 2b trials of Tezspire (tezepelumab-ekko) in broad asthma patient population. Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). The positive opinion covers Dupixent as an add-on maintenance treatment for severe asthma children aged 6 to 11...

4D pharma plc (NASDAQ: LBPS) has announced additional clinical data from Part A of its Phase 1/2 trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic for asthma.  As previously announced, Part A met the primary endpoint, and the safety profile of MRx...

Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target peak and sustained reduction of CD6 at Day 85 (one month following the last dose).  The data, collected from a total...

The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire was approved following a Priority Review by...

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November and the remainder in February 2022. The Company sees a total annualized operating expense savings of approximately $165...

Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of albuterol and budesonide developed by AstraZeneca Plc (NASDAQ: AZN) and Avillion. The trials met all primary...

Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication of respiratory disease. New data demonstrated that tezepelumab reduced exacerbations and improved lung function and nasal...

The FDA has accepted for review Amgen Inc's (NASDAQ: AMGN) marketing application seeking approval for tezepelumab to treat asthma.  Amgen is developing Tezepelumab in collaboration with AstraZeneca plc (NASDAQ: AZN). Under priority review status, the agency's...

AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating Fasenra (benralizumab) in adult patients with severe asthma. Results were presented today at the American Thoracic Society...

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent (dupilumab) in children aged 6 to 11 years for the treatment of asthma. In a phase 3 trial called Voyage, Dupixent...